Nova Patents
ATE320271T1

Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods

Abstract

The present invention is directed to novel replication-deficient adenoviral vectors characterized in that they harbor at least two lethal early region gene deletions (E1 and E4) that normally transcribe adenoviral early proteins. These novel recombinant vectors find particular use in human gene therapy treatment whereby the vectors additionally carry a transgene or therapeutic gene that replaces the E1 or E4 regions. The present invention is further directed to novel packaging cell lines that are transformed at a minimum with the adenoviral E1 and E4 gene regions and function to propagate the above novel replication-deficient adenoviral vectors.

Term

Term ended

Projected expiry passed 3 November 2015, 10.9 years ago.

  1. Priority
  2. Filed
  3. Published
  4. Projected expiry
  5. Today

19 members in 9 offices

This recordMember, by publication datePriority claim

Priority claims1

Priority claims
DocumentOfficeKindDate
33368094United States of AmericaA

Members19

Family members, oldest first
DocumentOfficeKind
CA2204357A1CanadaA1
WO9614061A1World Intellectual Property Organization (WIPO)A1
AU4109296AAustraliaA
EP0797436A1European Patent Office (EPO)A1
KR970706806ARepublic of KoreaA
JPH10508491AJapanA
US5872005AUnited States of AmericaA
EP0797436A4European Patent Office (EPO)A4
AU6557199AAustraliaA
US2002168342A1United States of AmericaA1
AU756629B2AustraliaB2
EP0797436B1European Patent Office (EPO)B1
AT320271TAustriaT
ATE320271T1This recordAustriaT1
DE69534878D1GermanyD1
DE69534878T2GermanyT2
CA2204357CCanadaC
JP2008200043AJapanA
JP4167725B2JapanB2